Stay updated with the latest biosimilar news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on biosimilar topics.
New Delhi, Jul 12 (PTI) Anthem Biosciences has raised Rs 1,016 crore from anchor investors ahead of its initial share-sale opening for public subscription. Some of the investors that participated in the anchor book are -- Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF, according to a circular uploaded on BSE's webs ...Read More >
New Delhi, Jul 9 (PTI) Anthem Biosciences on Wednesday fixed a price band of Rs 530 to Rs 570 for its Rs 3,395-crore initial public offering (IPO). At the upper end of the price band, the company's evaluation exceeds Rs 31,800 crore. The initial share-sale will be open for public subscription during July 14-16 and the one-day bidding for anchor investors is scheduled for July 11, the company said. The proposed IPO is entirely an offer-for-sale (OFS) worth Rs 3,395 crore by promoters, investor ...Read More >
New Delhi, Jul 3 (PTI) Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has been granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases. The marketing authorisation for the European Union (EU) follows a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025, Biocon Ltd said in a regulatory filing. Vevzuo is auth ...Read More >
New Delhi, Jun 27 (PTI) Biocon Ltd on Friday said its arm Biocon Biologics has been granted a notice of compliance by Health Canada for its biosimilar Yesafili injection used to treat various ailments of the eye. "Health Canada has granted a Notice of Compliance (NOC) for Yesafili(aflibercept), a biosimilar to Eylea injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025," a regulatory filing by Biocon said. This approval paves the way for the launch of Yesafili i ...Read More >
Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global markets. Keytruda (generic name is pembrolizumab), manufactured and marketed by Merck & Co, is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of cancer. Under the terms of the agreement, both ...Read More >
Seoul: South Korea's exports of bio-health products jumped 22.5 per cent in the third quarter from a year earlier, data showed on Friday, driven by growing demand for pharmaceutical goods in European nations. According to the Korea Health Industry Development Institute, outbound shipments of bio-health products, including pharmaceutical goods and cosmetics, amounted to $6.34 billion in the July-September period, compared with $5.17 billion recorded over the same period in 2023, Yonhap news agen ...Read More >
The shortage of qualified healthcare professionals, coupled with the rising prevalence of diabetes, creates a critical health challenge in Ethiopia Biocon Biologics shared the progress of the ongoing 'Embedding Specialist Nurses in Diabetes Care' project undertaken in collaboration with Diabetes Africa and St Paul's Hospital Millennium Medical College in Ethiopia. The first phase of this multi-year project has harnessed the expertise of key stakeholders in Ethiopia's diabetes ecosystem to dev ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.